2026-04-19T11:40:48Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/86882025-11-26T05:33:18Zcom_2072_378071com_2072_378040col_2072_378097
RECERCAT
author
Molist Muñoz, Carla
author
Zarzosa Martinez, Patricia
author
Gallo, Gabriel Osvaldo
author
Pons Barcons, Guillem
author
Magdaleno Cazon, Ainara
author
Hladun Alvaro, Raquel
author
Segura Ginard, Miguel
author
Sánchez de Toledo Codina, Josep
author
Moreno Martín-Retortillo, Lucas
author
Gallego Melcón, Soledad
author
Roma Castanyer, Josep
author
Navarro Barea, Natalia
author
Sansa Girona, Júlia
author
Guillén Burrieza, Gabriela
author
Garrido Pontnou, Marta
2022-12-19T13:07:46Z2022-12-19T13:07:46Z2022-10-11
Dissemination; Paediatric cancer; Solid tumoursDiseminación; Cáncer pediátrico; Tumores sólidosDisseminació; Càncer pediàtric; Tumors sòlidsThe majority of current cancer therapies are aimed at reducing tumour growth, but there is lack of viable pharmacological options to reduce the formation of metastasis. This is a paradox, since more than 90% of cancer deaths are attributable to metastatic progression. Integrin alpha9 (ITGA9) has been previously described as playing an essential role in metastasis; however, little is known about the mechanism that links this protein to this process, being one of the less studied integrins. We have now deciphered the importance of ITGA9 in metastasis and provide evidence demonstrating its essentiality for metastatic dissemination in rhabdomyosarcoma and neuroblastoma. However, the most translational advance of this study is to reveal, for the first time, the possibility of reducing metastasis by pharmacological inhibition of ITGA9 with a synthetic peptide simulating a key interaction domain of ADAM proteins, in experimental metastasis models, not only in childhood cancers but also in a breast cancer model.This research was supported by grants from: Institut Català d’Oncologia (ICO); Instituto de Salud Carlos III (PI18/00398 and FI18/00178); ACCIÓ (COMRDI15-1-0014); Fundació la Marató de TV3; Fundació A. BOSCH; Rotary Clubs Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst e.V. and others from Barcelona and province; Eric Abidal Foundation; Del Hospital a la catedral Initiative by Xavi Vallès; and Mi compañero de viaje Association.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Tumors de parts toves - Tractament
Sarcoma - Tractament
Retina - Càncer - Tractament
Metàstasi
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Neoplasms, Muscle Tissue::Myosarcoma::Rhabdomyosarcoma
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Retinoblastoma
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Integrins
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::miosarcoma::rabdomiosarcoma
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::retinoblastoma
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores inmunológicos::integrinas
Otros calificadores::Otros calificadores::/uso terapéutico
Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion